#NACinCOVID is website organizing information and research around the use of N-acetylcysteine (NAC) as an adjuvant therapy for treatment of COVID-19 illness.

Multiple agents, therapies and preventive measures are being studied as potential treatment for patients infected by SARS-CoV-2, the virus that causes COVID-19 disease. 

As of April 2020, at least 244 clinical trials involving an intervention on infected patients or infection prevention in uninfected patients were ongoing worldwide. (Lythgoe et al)

Major treatment strategy categories have included: 

N-acetylcysteine (NAC), a precursor to the amino acid L-cysteine used to improve the body’s ability to overcome oxidative stress, in appropriate and high-enough doses, may be an effective adjunctive therapy in treating patients infected by SARS-CoV-2 due its properties as

(1) Antioxidant

(2) Anti-inflammatory & immunomodulatory agent

(3) Antiviral agent, and

(4) Anticoagulant/antithrombotic